A retrospective study over five years in Northern Tunisia showed a higher incidence of acute myeloid leukemia (AML) then acute lymphoid leukemia (ALL). The current classification of AML based on cytology, cytochemistry, immunophenotyping and cytogenetic is not sufficiently powerful to predict prognosis, and clinical outcome remains poor with 40% of patients failing to achieve complete remission after induction therapy. We used DNA microarray technology to help providing new tools for subgroup classification. In our study we compared the expression profile of M5 AML patients to normal individual cells and found 82 regulated genes which are known to be implicated in several processes including apoptosis, transcription, differentiation and leukemogenesis. Some of these differentially expressed genes, guanine nucleotide binding protein gamma 11, tumor necrosis factor alpha-induced protein 3, protein kinase c eta, amphiregulin, lymphoid enhancer-binding factor 1, insulin-like growth factor binding protein 7, proteine tyrosine kinase 7 and myeloperoxydase are already currently being evaluated by quantitative PCR for validation of microarray analysis. Other sets of genes will be next tested until we obtain a precise pattern of leukemic gene expression. The relevancy of this pattern will be then assessed on a broader cohort of patients.
98th AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA